Previous close | 559.00 |
Open | 558.00 |
Bid | 554.00 x 0 |
Ask | 556.00 x 0 |
Day's range | 553.00 - 560.00 |
52-week range | 426.50 - 597.00 |
Volume | |
Avg. volume | 19,113 |
Market cap | 12.913B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 13.30 |
EPS (TTM) | 41.65 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | 16.00 (2.86%) |
Ex-dividend date | 11 Apr 2024 |
1y target est | 678.33 |
Tuesday, Schouw & Co. released its interim report for the first quarter of 2024; As expected, consolidated revenue for Q1 2024 was down on the year before, driven by a combination of lower prices and a drop in volume sales. EBITDA, on the other hand, increased strongly with BioMar as the main contributor, and cash flows from operations improved as well. Highlights DKK 7.9bn revenue – a reduction of 9%DKK 652m EBITDA – an increase of 28%DKK 171m cash flows from operations – an increase of DKK 266
Schouw & Co. will today be releasing its interim report for the first quarter of 2024. The interim report contains inside information, as the guidance for full-year revenue and EBITDA differs from the guidance expressed in the company’s annual report for 2023 released on 1 March 2024. The Group lowers its guidance for FY 2024 consolidated revenue to the range of DKK 34.8-37.2 billion from previously DKK 35.3-37.8 billion. At the same time, the guidance for FY 2023 consolidated EBITDA is raised t
On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“S